GS 5829

Drug Profile

GS 5829

Alternative Names: GS5829

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Prostate cancer
  • Phase I Lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 11 Oct 2017 Gilead Sciences completes a phase I trial in Solid tumours (Late-stage disease, Refractory metastatic disease), Lymphoma (Late-stage disease, Refractory metastatic disease) and Breast cancer (Combination therapy, Late-stage disease) in USA (PO) (NCT02392611)
  • 01 Jan 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02983604)
  • 03 Dec 2016 Pharmacokinetics and Pharmacodynamics data from preclinical trial in Diffuse large B cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (3218946; 3224662)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top